142 related articles for article (PubMed ID: 8666012)
1. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.
Benazzouz A; Boraud T; Dubédat P; Boireau A; Stutzmann JM; Gross C
Eur J Pharmacol; 1995 Sep; 284(3):299-307. PubMed ID: 8666012
[TBL] [Abstract][Full Text] [Related]
2. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
Bezard E; Stutzmann JM; Imbert C; Boraud T; Boireau A; Gross CE
Eur J Pharmacol; 1998 Sep; 356(2-3):101-4. PubMed ID: 9774238
[TBL] [Abstract][Full Text] [Related]
3. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Boraud T; Bezard E; Stutzmann JM; Bioulac B; Gross CE
Neurosci Lett; 2000 Mar; 281(2-3):75-8. PubMed ID: 10704746
[TBL] [Abstract][Full Text] [Related]
4. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Boireau A; Dubedat P; Bordier F; Imperato A; Moussaoui S
Neuropharmacology; 2000 Apr; 39(6):1016-20. PubMed ID: 10727711
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH
Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of riluzole in MPTP-treated mice.
Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
[TBL] [Abstract][Full Text] [Related]
7. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
[TBL] [Abstract][Full Text] [Related]
8. Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment.
Benazzouz A; Boraud T; Féger J; Burbaud P; Bioulac B; Gross C
Mov Disord; 1996 Nov; 11(6):627-32. PubMed ID: 8914087
[TBL] [Abstract][Full Text] [Related]
9. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys.
Benazzouz A; Gross C; Féger J; Boraud T; Bioulac B
Eur J Neurosci; 1993 Apr; 5(4):382-9. PubMed ID: 8261116
[TBL] [Abstract][Full Text] [Related]
10. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Palfi S; Riche D; Brouillet E; Guyot MC; Mary V; Wahl F; Peschanski M; Stutzmann JM; Hantraye P
Exp Neurol; 1997 Jul; 146(1):135-41. PubMed ID: 9225746
[TBL] [Abstract][Full Text] [Related]
11. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
12. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.
Bryson HM; Fulton B; Benfield P
Drugs; 1996 Oct; 52(4):549-63. PubMed ID: 8891467
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Obinu MC; Reibaud M; Blanchard V; Moussaoui S; Imperato A
Mov Disord; 2002 Jan; 17(1):13-9. PubMed ID: 11835434
[TBL] [Abstract][Full Text] [Related]
15. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
16. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
17. [Study of an MPTP-induced parkinsonian animal model in the rhesus monkey and the mechanism of the action of MPTP].
Chen S
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1990 Feb; 23(1):23-6, 62. PubMed ID: 1971785
[TBL] [Abstract][Full Text] [Related]
18. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
Bezard E; Imbert C; Deloire X; Bioulac B; Gross CE
Brain Res; 1997 Aug; 766(1-2):107-12. PubMed ID: 9359593
[TBL] [Abstract][Full Text] [Related]
19. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey.
Crossman AR; Peggs D; Boyce S; Luquin MR; Sambrook MA
Neuropharmacology; 1989 Nov; 28(11):1271-3. PubMed ID: 2687716
[TBL] [Abstract][Full Text] [Related]
20. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease.
Li H; He Z; Su T; Ma Y; Lu S; Dai C; Sun M
Neurol Res; 2003 Apr; 25(3):263-7. PubMed ID: 12739234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
